Granulomatous myositis: A clinical study of thirteen cases
✍ Scribed by Karine Le Roux; Nathalie Streichenberger; Christophe Vial; Philippe Petiot; Leonard Feasson; Françoise Bouhour; Jacques Ninet; Florence Lachenal; Christiane Broussolle; Pascal Sève
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 97 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0148-639X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Granulomatous myositis (GM) is a rare condition that has generally been described in association with sarcoidosis. In the absence of sarcoidosis or other underlying disease, a diagnosis of isolated GM is considered. Only one study has focused on the clinical difference between isolated GM and sarcoid myopathy (SM). We report 13 cases of symptomatic GM; 8 had sarcoidosis. All patients with sarcoidosis had predominantly proximal, symmetrical lower‐limb weakness, and 3 subsequently developed upper‐limb or distal involvement. Three of the five patients with isolated GM had predominantly distal muscle involvement, and two had dysphagia. Corticosteroid treatment was followed by prolonged improvement in only one patient with sarcoidosis. One patient had acute sarcoid myositis and benefited from methotrexate; other immunosuppressants and etanercept proved ineffective in chronic sarcoid myopathy. Three of the five patients with isolated GM responded to corticosteroid treatment. When last examined, three patients with sarcoidosis had severe disability, whereas patients with isolated GM showed milder weakness. Thus, SM was frequently associated with severe disability and rarely improved after corticosteroid treatment, whereas most patients with isolated GM improved. Muscle Nerve, 2006
📜 SIMILAR VOLUMES
Retrospective clinicopathological study of 125 thyroid carcinoma cases followed for 9 to 19 years was performed. Case selection for unfavorable histologic type and advanced disease was observed for referred cases. All medullary and anaplastic tumors were in patients over age 40; younger patients all
## Background: We evaluated the clinical features, treatment, and survival status of the patients with borderline ovarian tumors. Methods: A retrospective review of the charts of 150 patients with borderline ovarian tumor registered at the Tokai Ovarian Tumor Study Group from January 1, 1980, to D